Soligenix Inc. (SNGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Soligenix Inc. (SNGX) has a cash flow conversion efficiency ratio of -0.386x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.93 Million) by net assets ($7.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Soligenix Inc. market capitalisation for the company's overall valuation and market capitalisation.
Soligenix Inc. - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Soligenix Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Soligenix Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Soligenix Inc. ranked by their cash flow conversion efficiency. Explore cash flow quality index of Soligenix Inc. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Revelation Biosciences Inc
NASDAQ:REVB
|
-0.254x |
|
Techfast Holdings Bhd
KLSE:0084
|
0.129x |
|
Basin Energy Ltd
AU:BSN
|
-0.041x |
|
Cash.Medien AG
HM:MF8
|
N/A |
|
GreenPower Motor Company Inc
NASDAQ:GP
|
-0.021x |
|
Essentra PLC
LSE:ESNT
|
0.024x |
|
E-Home Household Service Holdings Ltd
NASDAQ:EJH
|
0.004x |
|
GGL Resources Corp
V:GGL
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Soligenix Inc. (1995–2024)
The table below shows the annual cash flow conversion efficiency of Soligenix Inc. from 1995 to 2024. View Soligenix Inc. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.12 Million | $-8.40 Million | -2.041x | +40.17% |
| 2023-12-31 | $2.52 Million | $-8.60 Million | -3.411x | -166.63% |
| 2022-12-31 | $-2.47 Million | $-12.65 Million | 5.119x | +567.59% |
| 2021-12-31 | $10.72 Million | $-11.74 Million | -1.095x | +64.23% |
| 2020-12-31 | $3.74 Million | $-11.45 Million | -3.061x | +40.60% |
| 2019-12-31 | $1.46 Million | $-7.51 Million | -5.154x | -346.76% |
| 2018-12-31 | $6.28 Million | $-7.24 Million | -1.154x | -11.98% |
| 2017-12-31 | $6.32 Million | $-6.51 Million | -1.030x | -52.95% |
| 2016-12-31 | $7.40 Million | $-4.98 Million | -0.674x | -100.23% |
| 2015-12-31 | $-18.31K | $-5.39 Million | 294.189x | +1735.32% |
| 2014-12-31 | $-153.89K | $-2.47 Million | 16.029x | +536.51% |
| 2013-12-31 | $-1.77 Million | $-4.46 Million | 2.518x | +439.32% |
| 2012-12-31 | $3.55 Million | $-2.64 Million | -0.742x | -158.24% |
| 2011-12-31 | $6.79 Million | $-1.95 Million | -0.287x | +63.10% |
| 2010-12-31 | $7.36 Million | $-5.73 Million | -0.779x | -38.31% |
| 2009-12-31 | $8.17 Million | $-4.60 Million | -0.563x | +60.07% |
| 2008-12-31 | $1.98 Million | $-2.79 Million | -1.410x | +39.09% |
| 2007-12-31 | $2.59 Million | $-6.00 Million | -2.315x | -161.97% |
| 2006-12-31 | $-1.11 Million | $-4.14 Million | 3.737x | +222.25% |
| 2005-12-31 | $1.53 Million | $-4.67 Million | -3.057x | -106.90% |
| 2004-12-31 | $2.98 Million | $-4.41 Million | -1.477x | -83.67% |
| 2003-12-31 | $5.24 Million | $-4.22 Million | -0.804x | +42.56% |
| 2002-12-31 | $4.29 Million | $-6.00 Million | -1.400x | -192.57% |
| 2001-12-31 | $-2.63 Million | $-3.98 Million | 1.513x | +562.42% |
| 2000-12-31 | $10.55 Million | $-3.45 Million | -0.327x | -20.07% |
| 1999-12-31 | $7.26 Million | $-1.98 Million | -0.272x | +2.32% |
| 1998-12-31 | $14.70 Million | $-4.10 Million | -0.279x | -123.13% |
| 1997-12-31 | $18.40 Million | $-2.30 Million | -0.125x | +90.67% |
| 1996-12-31 | $1.12 Million | $-1.50 Million | -1.339x | -84.15% |
| 1995-12-31 | $1.38 Million | $-1.00 Million | -0.727x | -- |
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the tre… Read more